DEA Revokes Doctor’s Controlled-Substance Registration After Virginia Authorization Ends
Published Date: 11/18/2026
Notice
Summary
Dr. Kyndahl D. Bertram lost her DEA registration because she no longer has permission to handle controlled substances in Virginia. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on July 31, 2026. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FB9918357 for Kyndahl D. Bertram, D.O. The revocation is effective December 18, 2026, and means she is not authorized to prescribe, administer, dispense, or otherwise handle controlled substances in Virginia.
Pending Renewal and New Registrations Denied
The DEA denied any pending applications by Kyndahl D. Bertram, D.O., to renew or modify her registration and denied any pending applications for additional registration in Virginia. That denial is ordered alongside the revocation and is effective December 18, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-23075, Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV
Starting November 12, 2026, the drug oveporexton (brand name Orzeyful), used to treat narcolepsy in adults, is officially placed in Schedule IV, meaning it’s recognized as having a low potential for abuse but still controlled by law. This change affects patients, doctors, and pharmacies by adding new rules for prescribing and handling the drug. You’ve got until December 14, 2026, to share your thoughts or request a hearing about this decision.
2026-23006, Importer of Controlled Substances Application: NSI Lab Solutions LLC
NSI Lab Solutions LLC wants to become an official importer of certain controlled substances, like Amineptine and Mesocarb. People who make or use these drugs can share their thoughts or ask for a hearing by December 14, 2026. This move could affect companies handling these substances and involves a formal review process with no immediate cost changes announced.
Previous / Next Documents
Previous: 2026-23511, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V ANNIE LAURIE
The Maritime Administration is asking for public comments on whether the foreign-built small passenger vessel M/V ANNIE LAURIE should be allowed to operate in U.S. coastal trade. This decision affects U.S. boat builders and businesses using U.S.-built vessels, with comments due by December 18, 2026. It’s a chance to weigh in on protecting American jobs while considering new vessel use.
Next: 2026-23515, Notice of Revised National Environmental Policy Act Implementing Procedures
The Department of Homeland Security is updating its rules for how it checks the environment before starting projects. These changes make the process faster, clearer, and easier to follow, helping avoid delays and extra costs. Everyone involved in DHS projects should check out the new draft and send their thoughts by December 18, 2026.